A Phase 4 interventional study of Levomilnacipran ER and Placebo in Depressive Disorder, Major, sponsored by Forest Laboratories. Completed at 47 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-10-29.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing levomilnacipran in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. Levomilnacipran · Depressive Disorder, Major.
Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 4, and was the 8th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →None of the 14 studies testing levomilnacipran in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →
Levomilnacipran: first FDA approval 2013 (FETZIMA). What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 644 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 472 across the 14 interventional studies. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
53 studies in Depressive Disorder, Major by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 50 finished, 37 (74%) have results posted.
Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 13th largest by enrollment, is one of 4 that started in 2014, is one of 6 in phase 4, and was the 31st registered.
AbbVie’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 53 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse in major depressive disorder (MDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FETZIMA® (levomilnacipran extended release \[ER\]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
Drug: Levomilnacipran ER
Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
Drug: Placebo
FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
Drug: Levomilnacipran ER
Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.
Also known as: FETZIMA®
Dose-matched placebo taken orally once daily.
Time to First Relapse During the Double-Blind Treatment Period (DBTP)
Time to relapse for the median was measured in days from randomization date at the start of the DBTP to relapse date during DBTP. Relapse was defined as meeting any 1 or more of the following criteria: 1) Insufficient therapeutic response at any one visit, including a \>/= 2 increase in Clinical Global Impressions-Severity (CGI-S) score (range 1 to 7) compared with that obtained at randomization, or risk of suicide as determined by the investigator, or need for hospitalization due to worsening of depression as determined by the investigator, or need for alternative treatment of depressive symptoms as determined by the Investigator; 2) Montgomery-Asberg Depression Rating Scale (MADRS) total score \>/= 18 (range 0 to 60) at 2 consecutive visits (second visit within 7 to 14 days after the first visit at which the MADRS total score was ≥ 18). Participant was considered censored at the last visit during DBTP if participant did not meet the relapse criteria during DBTP.
Time frame: From the randomization date (Week 20) to the relapse date during the 26-week DBTP (up to Week 46)
| Milestone | Open-Label FETZIMA® | Double-Blind Placebo | Double-Blind FETZIMA® |
|---|---|---|---|
| Started | 644 | 0 | 0 |
| Completed | 499 | 0 | 0 |
| Not completed | 145 | 0 | 0 |
| Withdrew: Adverse event | 48 | 0 | 0 |
| Withdrew: Lack of efficacy | 16 | 0 | 0 |
| Withdrew: Withdrawal of consent | 28 | 0 | 0 |
| Withdrew: Lost to follow-up | 25 | 0 | 0 |
| Withdrew: Protocol violation | 17 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 3 | 0 | 0 |
| Withdrew: Reason not specified | 8 | 0 | 0 |
| Milestone | Open-Label FETZIMA® | Double-Blind Placebo | Double-Blind FETZIMA® |
|---|---|---|---|
| Started | 429 | 0 | 0 |
| Completed | 331 | 0 | 0 |
| Not completed | 98 | 0 | 0 |
| Withdrew: Adverse event | 13 | 0 | 0 |
| Withdrew: Lack of efficacy | 22 | 0 | 0 |
| Withdrew: Withdrawal of consent | 23 | 0 | 0 |
| Withdrew: Lost to follow-up | 12 | 0 | 0 |
| Withdrew: Protocol violation | 8 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 5 | 0 | 0 |
| Withdrew: Reason not specified | 15 | 0 | 0 |
| Milestone | Open-Label FETZIMA® | Double-Blind Placebo | Double-Blind FETZIMA® |
|---|---|---|---|
| Started | 0 | 159 | 165 |
| Completed | 0 | 135 | 139 |
| Not completed | 0 | 24 | 26 |
| Withdrew: Adverse event | 0 | 2 | 5 |
| Withdrew: Withdrawal of consent | 0 | 8 | 8 |
| Withdrew: Lost to follow-up | 0 | 4 | 5 |
| Withdrew: Protocol violation | 0 | 1 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 4 |
| Withdrew: Multiple reasons | 0 | 8 | 2 |
Time to relapse for the median was measured in days from randomization date at the start of the DBTP to relapse date during DBTP. Relapse was defined as meeting any 1 or more of the following criteria: 1) Insufficient therapeutic response at any one visit, including a \>/= 2 increase in Clinical Global Impressions-Severity (CGI-S) score (range 1 to 7) compared with that obtained at randomization, or risk of suicide as determined by the investigator, or need for hospitalization due to worsening of depression as determined by the investigator, or need for alternative treatment of depressive symptoms as determined by the Investigator; 2) Montgomery-Asberg Depression Rating Scale (MADRS) total score \>/= 18 (range 0 to 60) at 2 consecutive visits (second visit within 7 to 14 days after the first visit at which the MADRS total score was ≥ 18). Participant was considered censored at the last visit during DBTP if participant did not meet the relapse criteria during DBTP.
| days | Double-Blind Placebo | Double-Blind FETZIMA® |
|---|---|---|
| Time to First Relapse During the Double-Blind Treatment Period (DBTP) | NA (NA to NA) | NA (NA to NA) |
Collected over Up to 48 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-Label FETZIMA® | 0/644 (0%) | 9/644 (1.4%) | 430/644 (66.8%) |
| Double-Blind Placebo | 0/159 (0%) | 1/159 (0.6%) | 29/159 (18.2%) |
| Double-Blind FETZIMA® | 0/165 (0%) | 2/165 (1.2%) | 41/165 (24.8%) |
| Event | Open-Label FETZIMA® | Double-Blind Placebo | Double-Blind FETZIMA® |
|---|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 0/644 | 1/159 | 0/165 |
| Transient ischaemic attackNervous system disorders | 0/644 | 0/159 | 1/165 |
| Escherichia pyelonephritisInfections and infestations | 0/644 | 0/159 | 1/165 |
| Panic attackPsychiatric disorders | 1/644 | 0/159 | 0/165 |
| Oesophageal squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/644 | 0/159 | 0/165 |
| MigraineNervous system disorders | 1/644 | 0/159 | 0/165 |
| ManiaPsychiatric disorders | 1/644 | 0/159 | 0/165 |
| InfluenzaInfections and infestations | 1/644 | 0/159 | 0/165 |
| HyponatraemiaMetabolism and nutrition disorders | 1/644 | 0/159 | 0/165 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/644 | 0/159 | 0/165 |
| Event | Open-Label FETZIMA® | Double-Blind Placebo | Double-Blind FETZIMA® |
|---|---|---|---|
| NauseaGastrointestinal disorders | 174/644 | 5/159 | 13/165 |
| HeadacheNervous system disorders | 103/644 | 12/159 | 17/165 |
| Heart rate increasedInvestigations | 71/644 | 4/159 | 4/165 |
| ConstipationGastrointestinal disorders | 69/644 | 3/159 | 3/165 |
| Upper respiratory tract infectionInfections and infestations | 46/644 | 10/159 | 16/165 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 57/644 | 2/159 | 1/165 |
| DizzinessNervous system disorders | 50/644 | 4/159 | 1/165 |
| TachycardiaCardiac disorders | 50/644 | 3/159 | 6/165 |
| NasopharyngitisInfections and infestations | 25/644 | 7/159 | 11/165 |
| Dry mouthGastrointestinal disorders | 37/644 | 2/159 | 0/165 |
Run-in Phase (RIP) Safety Population comprised all participants in the screened population who took at least 1 dose of open-label levomilnacipran during the RIP.
| Age, Continuous(years) | Open-Label FETZIMA® |
|---|---|
| Mean | 43.1 ± 13.9 |
| Sex: Female, Male(Participants) | Open-Label FETZIMA® |
|---|---|
| Female | 404 |
| Male | 240 |
Ran from Nov 2014 to primary completion in Sep 2016, 21 months.
Results were first posted in Oct 2018, 2 years 1 month after primary completion.
Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levomilnacipran